Kornimate/medical-research-clean huggingface dataset:
self efficacy levels, attachment style and resiliency of youth with type 1 diabetes

Conditions: Type1diabetes

Summary: this project will assess self-efficacy levels(se) ,resiliency and attachment style of adolescent with type 1 diabetes and their caregivers.se and attachment style of patients and parents will be compared with each other as well as correlated with diabetes management as assessed by a1c and self inventory scale.


Eligibility criteria:
inclusion criteria: * t1dm patients age 12 - 18 yrs from sick kids diabetes clinic and a primary caregiver * t1dm \> 1yr and able to communicate in english exclusion criteria: * families who cannot communicate in english (read, write, speak) * diagnosed less than 1 year diabetes * transient form of diabetes (such as medication induced diabetes) * exclude type 2 diabetes and cfrd (cystic fibrosis related diabetes)

Keywords: self efficacy resiliency attachment style and youth with type 1 diabetes
evaluation of 3d ultrasound in brain tumor surgery

Conditions: Residual Tumor

Summary: evaluation of impact of use of 3d ultrasound in brain tumor surgery on extend of resection. benefit for surgery, neurological outcome, accuracy and image quality are secondary outcome parameters. control group is a retrospective matched pair cohort.


Eligibility criteria:
inclusion criteria: * age above 18 suspected intra-axial lesion (metastasis or glioma) potential gross total resection of lesion exclusion criteria: * no ability for informed consent
effect of melatonin on sleep disturbances in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: this clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.

after selecting patients who satisfied the inclusion criteria and were not disqualified by the exclusion criteria, through a double-blind procedure the patients are directed to orally take either the investigational drug melatonin or a placebo(allocation ratio 1:1) for 4 weeks, once daily, before going to sleep. the evaluation of efficacy and safety is performed at the first baseline and immediately after administering the drug for 4 weeks.

Eligibility criteria:
inclusion criteria: 1. patients who meet the clinical criteria for idiopathic parkinson's disease (united kingdom parkinson's disease brain bank criteria) 2. patients who complain of sleep disturbances such as insomnia, rem sleep behavior disorder, excessive daytime sleepiness (eds), etc. 3. patients who have received drug treatment for at least 6 months since their diagnosis 4. male or female patient aged 55 or older 5. patients who have given voluntary consent after understanding the content of the clinical trial (in the case of elderly patients aged 70 or older, consent must be received from both the subject and the his or her legal representative) exclusion criteria: 1. patients with a serious cognitive disorder, behavioral disorder, or mental illness 2. patients with a serious medical disease * patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease * patients with un-controlled high blood pressure or diabetes 3. patients who have taken another drug under clinical trial within 4 weeks prior to registering for this clinical trial, or patients who are pregnant or breastfeeding 4. patients who have a history of hypersensitivity to the investigational drug or a drug similar in component or who have had heavy metal poisoning 5. patients who are taking drugs which could effect on sleep such as rivotril, quetiapine, lexapro, etc.

Keywords: melatonin sleep disturbances
patient satisfaction with virtual post operative visits: hip arthroscopy

Conditions: Femoroacetabular Impingement

Summary: this is a prospective, randomized study designed to evaluate the effects of different initial postoperative follow-up modalities. given the nature of the study, it is not possible for either the surgeons or the subjects to be blinded. patients will be assigned to either group based on the last digit of their medical record number (mrn). patients with an even-ending medical record number will be randomized to virtual visit/telemedicine, while patients with an odd-ending medical record number will be randomized to the office visit.

this study aims to evaluate the differences between two forms of postoperative follow-up with respect to patient satisfaction. the primary outcome will be patient satisfaction with their surgeon and with their overall experience. following their second postoperative visit, the subjects will complete one electronic survey. the survey is designed to assess subject's overall satisfaction and satisfaction with their surgery. this survey is standardized and will be used by both groups.

Eligibility criteria:
inclusion criteria: * participants undergoing arthroscopic hip surgery exclusion criteria: * age \ 70 years old
atenolol for the prevention of osteoporosis (apo)

Conditions: Healthy

Summary: evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.


Eligibility criteria:
inclusion criteria: * able and willing to provide informed consent * postmenopausal women (fsh ≥ 16 iu/l) (no menses for at least one year) * aged 50-75 years exclusion criteria: * clinical diagnosis of diabetes mellitus requiring insulin * clinically significant abnormality in any of the additional screening laboratory studies * a1c- ≥8 * calcium - \> upper limit lab value per site * ast- 2x upper normal limit * fsh- \< 16iu/l * egfr- \< 45 ml/min/1.73m2 based on creatinine * cbc- per pi interpretation of each patient * presence of (documented clinical diagnosis of any of the following): * significant liver or renal disease * malignancy (current diagnosis including myeloma or melanoma) * radiation (the site pi will determine eligibility on a case-by-case basis) * malabsorption (current clinical diagnosis or actively receiving treatment) * hypoparathyroidism (current clinical diagnosis or actively receiving treatment) * hyperparathyroidism (current clinical diagnosis or actively receiving treatment) * acromegaly * cushing syndrome * hypopituitarism * severe chronic obstructive pulmonary disease * pheochromocytoma (current clinical diagnosis or actively receiving treatment) * history of cardiac failure * ejection fraction \<35% (based on most recent ef within the last 12 months, if available) * pr interval \> 200 msec on screening ecg or known heart block * history of bronchospastic disease with treatment (asthma, bronchitis) * gastric bypass * parkinson's * rheumatoid arthritis * psoriatic arthritis * connective tissue disease * undergoing treatment with any medications that affect bone turnover, including the following: * adrenocorticosteroids (oral for \> 3 months within the past year or year-round use of inhaled corticosteroid use) * anticonvulsant therapy for seizures (carbamazepine, phenobarbital, or phenytoin within the previous year) pharmacological doses of: thyroid hormone (causing decline of thyroid stimulating hormone below normal, i.e. \ 1 month in past 3 years) denosumab, romosozumab, estrogen therapy (does not include creams or suppositories) or treatment with a selective estrogen receptor modulator, or teriparatide/abaloparatide (\> 1 month within the past year); aromatase inhibitors (\>1 month within the past year) * current use of digitalis glycosides * thiazides (\< 6 months of use prior to screening) * current or within the past 3 months use of beta blockers * any recent fracture within the past 6 months prior to screening (other than fingers, toes and facial fractures, which are all acceptable) * bilateral hip replacements or metal in both hips * patients with serum 25-hydroxyvitamin d levels of \< 20 ng/ml, in order to ensure vitamin d sufficiency * resting systolic blood pressure \< 115 mm hg, heart rate \< 55 bpm (average of 3 readings after a 5-minute rest and one minute between readings with an automatic cuff)
corneal transplantation guided by oct rescan

Conditions: Cornea; Keratoconus; Bullous Keratopathy; Corneal Dystrophy

Summary: the investigators will evaluate 30 patients with surgical indication for corneal transplantation. participants will be divided according to the following diseases diseases: keratoconus, bullous keratopathy, corneal dystrophies. participants will be informed about the risks and benefits of the study and sign an informed consent form. in the preoperative evaluation will be submitted to a complete ophthalmologic examination with complementary tests, such as optical coherence tomography. one group of participants will undergo corneal surgery using the oct lumera microscope rescan - zeiss and another group with a conventional microscope. everyone will have their filmed and documented surgery. the team of surgeons will answer the questionnaire on the surgical difficulty about the ease of assessing corneal transplantation. after surgery, participants will be assessed on days 1, 7,15, 30, 60, 90 and 180 after surgery. surgeries and study procedures will be performed by the same team of surgeons and performed by ipepo - paulista institute of studies and research in ophthalmology / vision institute.

participants will be allocated in one of the following groups: 1. control group the control group will undergo corneal transplant with conventional microscope without coupled oct. the team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation (annex 1). 2. group oct rescan in the group microscope coupled to oct, patients will undergo retinal surgery using the lumera microscope with rescan oct - zeiss. the team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation (annex 1). the investigators will evaluate intraoperative conditions, complications, operative time and postoperative results in both groups. all patients will be monitored and evaluated with full ophthalmological examination in all postoperative visits (day 1, 7,15,30, 60, 90, 180) and will be subjected to the following tests: * measurement of visual acuity with best correction * previous biomicroscopy * corneal topography * tonometry * optical coherence tomography (oct) * microscopy speculate

Eligibility criteria:
inclusion criteria: * visual acuity less than 20/60 in the affected eye * 18 years at least * diagnostic of the following diseases: * keratoconus * keratopathy bullosa * corneal dystrophy exclusion criteria: * better visual acuity than or equal to 20/60

Keywords: keratoconus bullous keratopathy corneal dystrophy
gastric volume in the fasted pediatric cerebral palsy patients

Conditions: Aspiration, Respiratory; Cerebral Palsy

Summary: in children with cerebral palsy, the gastric volume is measured through ultrasound after fasting before surgery to evaluate whether the risk of aspiration is higher than that of the general population.


Eligibility criteria:
inclusion criteria: * patients with cerebral palsy under the age of 18 undergoing surgery under general anesthesia exclusion criteria: * levin tube or gastrostomy tube in situ * decline to participate
vancomycin tissue concentrations by bier block or intravenous administration

Conditions: Infection; Hand Injury Wrist; Hand Injuries; Hand Injuries and Disorders; Hand Arthritis

Summary: the purpose of this study is to determine whether or not giving a lower dose of antibiotics (vancomycin) in the area where it is needed (upper extremity) is more effective at preventing infection than the current standard dose which is given intravenously (iv).


Eligibility criteria:
inclusion criteria: * patients undergoing upper extremity reconstruction by a single surgeon. * surgical cases will include: * trapeziectomy/suspensionplasty. * pipj/mpj arthroplasty. * proximal row carpectomy. * distal ulnar resection. * distal radius fracture fixation. exclusion criteria: * inability to adequately cannulate a superficial vein in the upper extremity within 5 minutes of tourniquet inflation. * evidence of subcutaneous extravasation in bier block group. * history of renal dysfunction. * vancomycin allergy. * asa\>/= 3. * history of lung cancer. * known hiv infection. * history of organ transplantation.
polar wand carbon dioxide cryotherapy for barrett's esophagus

Conditions: Barrett's Esophagus

Summary: the purpose of this pilot study is to provide an initial assessment of the feasibility, safety and efficacy of polar wand carbon dioxide cryotherapy for treatment of barrett's low grade and high grade dysplasia by use in a small number of patients so as to support, or otherwise, the development of a full-scale trial.

prospective pilot study to be performed in 14 barrett's esophagus patients with low grade and high grade dysplasia, referred for standard of care treatment. patients will receive treatments with carbon dioxide polar wand cryotherapy at 0, 2 and 4 months, followed by surveillance endoscopy with four quadrant biopsies throughout the entire barrett's esophagus (be)segment at 6 months, followed by endoscopy with additional treatments (if needed) at 8 and 10 months, followed by a final surveillance endoscopy at 12 months, with four quadrant biopsies throughout the entire initial be segment length.

Eligibility criteria:
inclusion criteria: * patients referred for treatment with barrett's esophagus with dysplasia as the original indication for ablative treatment. * previous fundoplication surgery is permitted * age 18 years to 98 years * ability to provide written, informed consent exclusion criteria: * inability to obtain biopsies due to anticoagulation, varices, etc. * previous ablation therapy, wide area mucosal resection or external beam radiation to the thorax. * intolerance to twice daily proton pump inhibitor medication or inability to undergo sedation or endoscopic procedures. * worse than grade b erosive esophagitis * less than 3 weeks from previous endoscopy with biopsy or 6 weeks from previous endoscopic therapy (resection).

Keywords: barrett's esophagus dysplasia
single ascending dose study of prx003 in healthy subjects

Conditions: Psoriasis

Summary: this single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of prx003 in approximately 40 healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy subjects * body mass index (bmi) between 18-32 kg/m2 with a minimum weight of 45 kg * female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception * male subjects and their partners of childbearing potential must use contraception exclusion criteria: * positive test for drug of abuse * past or current history of alcohol abuse * positive for tb, hepatitis b, hepatitis c or hiv infection
mechanisms and phenotypes of hypertension in patients in chronic hemodialysis

Conditions: Arterial Hypertension; Hemodialysis

Summary: the goal of this study is to evalluate the blood pressure changes of the patients in chronic hemodialysis. the main question to be answered is: what is the relative importance of weight gain, the renin angiotensin system, the sympathetic nervous system and inflammatory immune reactivity in the hypertension of patients in chronic hemodialysis, the participantes will have hemodynamic evaluation (cardiac output and peripheral vascular resistance) at the end of dialysis, ambulatory monitoring of blood pressure in the interdialytic period and before the next dialysis (2-3 days later). serum samples will be collected at the end of dialysis and before the start of the next dialysis, 2-3 days later.

this is a prospective observational study that will study stable patients in the chronic hemodialysis program of the incmnsz patients. there will be no modifications in the dialysis prescriptions and the patients with inclusion criteria will be studied after and before their usual hemodialysis sesion. * weight (kilograms) changes will be studied after dialysis and before the next dialysis sesion (2-3 days later) * serum samples will be obtained at the end of dialysis and before the next sesion (2-3 days later). * ultrasound estimation of cardiac output and peripheral vascular rersistance will be done after dialysis * ambulatory blood pressure monitoring will be done in the interdialytic period (24-48 hours) between the end of dialysis and the next dialysis sesion. * if possible there will be a predialysis study of bioimpedance. associations of weight gain (kilograms), serum angiotensin ii and angiotensin 1-7 (pg/ml), levels of il-6 (pg/ml), il-17 (pg/ml), il-10 (pg/ml), tnfalpha (pg/ml), copeptin levels(pg/ml) and norepinephrin levels (pg/ml) with systolic and diastolic blood pressure (mmhg) before and after dialysis will be explored. * phenotypes of blood pressure (sustained hypertension, nocturnal and diurnal hypertension, dippers, non-dippers, extreme dippers and reverse dippers) hypertension determined by ambulatory monitoring will be studied in relation of levels of angiotensin ii, immune inflammatory markers, copeptin and norepinephrin leves. all serum levels will be determined by commercial elisa kits,

Eligibility criteria:
inclusion criteria: -patients with more than 3 months in the chronic hemodialysis program in the incmnsz and assumed to remained in the program for longer than 3 months exclusion criteria: * patiens unable to give informed consent to the study * patients with active infection * patients with prostesis or pacemakers * patients with immunosuppresive treatment equivalent to more than 15mg prednisone daily

Keywords: kemodialysis, hypertension inflammation renin angiotensin system sympathetic nervous system
voice quality analysis of patients with laryngotracheal stenosis

Conditions: Idiopathic Subglottic Tracheal Stenosis

Summary: the investigators previously demonstrated that voice changes are common in patients with laryngotracheal stenosis (lts), and patients typically report an improvement in voice outcomes following endoscopic dilation. recently, nih based programs such as a bridge to artificial intelligence (bridge2ai) have highlighted the use of artificial intelligence to identify acoustic biomarkers of disease. therefore, the investigators hypothesize that progression of lts scar can be quantified using acoustic measurements and machine learning. the goal of this clinical trial is to remotely monitor patient voice quality in an effort to determine if regularly performed voice recordings can be used as a diagnostic tool in order to predict the need for dilation procedures. the investigators feel that successful use of remote voice recording technology with algorithmic analysis will improve patient quality of life.


Eligibility criteria:
inclusion criteria: * current diagnosis of laryngotracheal stenosis * patient age 18 - 80 years old * eastern cooperative oncology group (ecog) performance status of 0 - 1 * the patient must be able to comprehend and have signed the informed consent. * the patient must have documentation of their date of laryngotracheal stenosis diagnosis and prior medical/surgical history. exclusion criteria: * inability to use the app associated with the study. * comorbid laryngeal or glottic disease * concurrent neurological disease which may impact voice use (such as tremor, parkinsonism, laryngeal dystonia)

Keywords: tracheal stenosis voice quality
assessment of intravenous rate control response in atrial fibrillation trial (aircraft)

Conditions: Atrial Fibrillation

Summary: the assessment of intravenous rate control response in atrial fibrillation trial pilot study (aircraft pilot) is a prospective, unblinded, pragmatic, cluster-level allocation trial. aircraft compares two medication classes commonly used for rate control in patients in atrial fibrillation (af) with rapid ventricular rate (rvr). the purpose of this pilot study is to evaluate the feasibility and approach to conducting a trial that compares the use of iv beta blockers and iv calcium channel blockers for patients in af with rvr in the medical intensive care unit (micu). af with rvr is considered when the following parameters are met: (1) cardiac rhythm consistent with af (2) heart rate \> 110 bpm. af with rvr recurrence after conversion to sinus rhythm or prior rate control will count as a new episode of af with rvr. rate control agents will be pseudo-randomized to each of the three different micu teams (beta-blocker, calcium channel blocker and physician preference). patients are admitted to the three micu teams on a rotating basis which will allow for pseudo-randomization, the effects of which will be equal between the three teams. patients will be enrolled in the study if they develop af with rvr and will be followed until discharge from the micu. this study aims to assess the adherence and fidelity to treatment assignments in the current novel pilot study protocol which will help inform the feasibility of a larger-scale efficacy trial between iv beta blockers and iv calcium channel blockers for initial management of af with rvr. assessment of adherence and fidelity to treatment assignments in management of af with rvr in the micu will help inform power calculations and the percent of patients in each study group that received the assigned class of medication will help inform feasibility. additional aims include assessment of time from medication administration to rate control or sinus conversion as well as identifying optimal means of data extraction (manual vs automated), and incidence of adverse events including hypotension and bradycardia.


Eligibility criteria:
inclusion criteria: * all adults admitted to the micu at boston medical center (bmc) during the study period who develop af with rvr whose treating clinicians decides intravenous (iv) rate control agent is necessary to manage af with rvr * patients readmitted to the micu during the study period with recurrence of af with rvr after conversion to sinus rhythm or prior rate control exclusion criteria: * pregnancy * prisoners * allergies to study interventions * presentation consistent with acute asthma exacerbation * presentation consistent with acute systolic heart failure

Keywords: beta-blocker calcium channel blocker rapid ventricular rate (rvr)